Following promising results in disease treatment

Agemica founder recognized in King Charles III’s Birthday Honours as his AI-driven longevity platform advances toward in vivo testing. Professor Ronjon Nag, founder and CEO of longevity therapeutics company Agemica, has been appointed an Officer of the Order of the British Empire (OBE) in King Charles III’s Birthday Honours, being recognized for services to entrepreneurship and artificial intelligence [1]. The Birthday Honours are one of two major honours lists published each year as part of the UK’s national honors system, recognizing contributions across science, business, public service and the arts. While the award reflects Nag’s broader career in AI and technology entrepreneurship, it arrives at a moment when his attention is increasingly focused on aging biology and the application of artificial intelligence to age-related disease. From speech recognition to aging biology Nag’s career spans four decades of AI development. Having built an early speech-recognition system while an undergraduate at the University of Birmingham, he went on to study at Cambridge, MIT and Stanford, later founding companies whose technologies contributed to speech, handwriting recognition and predictive text systems adopted across the mobile industry. Today, through Agemica, he is applying those computational tools to a different challenge: identifying biological targets shared across…

New biomarkers, existing drugs and decades of ce

Voyager Therapeutics announced that Chief Executi

Sky Labs presented clinical and real-world data f

Cognision announced publication in Biological Psy

Lateral Pharma announced that peer-reviewed resea

Harness Therapeutics has been awarded a grant fro

Tectonic has completed enrollment in the APEX 24-

Heartseed, a Tokyo-based biotechnology company, d

AbbVie presented final Phase 3 CLL14 results for

A small Swedish biotech lands a potentially bill

NanoDetection secures global rights to antibody

The world’s smallest smart ring signals Oura’s move from wellness tracking toward proactive, personalized health guidance. Wearable technology is usually patterned as more sensors, more features, more data. Now, health tech company ŌURA is taking a different approach. Its newly unveiled Oura Ring 5 is 40% smaller than its predecessor, making it what the company calls the world’s smallest smart ring. Yet the significance of the launch isn’t really about size. Instead, ŌURA’s latest device points to a trend unfolding across the longevity sector: the transition from tracking health to helping people protect it actively [1]. Most wearables have become very good at telling users what happened yesterday. You slept poorly. Your heart rate was elevated. Your activity levels dropped. Useful information, certainly, but information alone rarely changes outcomes. The next generation of health technology is increasingly confronting a more difficult question: what happens next? “Oura Ring 5 is a big step toward our vision of giving every body a voice,” said Tom Hale, CEO at ŌURA. “By reimagining Oura Ring 5 to be smaller, easier to wear, and pairing it with our most advanced software yet, we’re making it possible for many more people to wear Oura every day…

New findings suggest OrsoBio’s energy-burning

Cathie Wood’s firm joins Cellares’ $277m fun

Rokit Healthcare announced it has received clinic

Tectonic Therapeutic has completed enrollment in

NeuroSense announced that the Korean Intellectual

Haut.

Heartseed has begun dosing patients in its domest

Melbourne-based Lateral Pharma announced that a p

Immorta Bio published a peer-reviewed study in th

Osteoboost’s State of Bones Report points to g

A mitochondrial therapy that leaves hunger untou

New Longevity Show blog argues that wellness pro

A 2,000-person study at Beijing’s renowned 301

New resource aims to help users navigate more th

Ab Science announced that new analyses from its p

Linnaeus Therapeutics announced that its lead can

MetaShape Pharma reported preclinical findings sh

AcCELLerated Biologics announced on 9 June 2026,

The Lung Cancer Research Foundation (LCRF), in co

Junevity has engaged Sunrise BioVentures as advis

New collaboration shifts the focus from slowing

The company’s latest platform update brings FD

Immorta Bio says the future of medicine may lie

C2N Diagnostics and SouthGenetics aim to bring e

Researchers from across disciplines will gather

Alterity Therapeutics reported a successful End-o

Houston-based Coya Therapeutics has started the b

AlzeCure has entered a collaboration and out-lice

MetaVia presented late-breaking Phase 1 and precl

Immorta Bio presented its AI-enabled, personalize

Based in Encinitas, Calif.

New funds and strategic collaboration with Merck

As regenerative medicine advances, preserving yo

New dried blood spot kit could make large-scale

IIOL Executive Director Tina Woods explains why

First patient dosed in Phase 1 trial testing epi